TORL Biotherapeutics Revenue and Competitors

Location

#6100

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • TORL Biotherapeutics's estimated annual revenue is currently $9.5M per year.(i)
  • TORL Biotherapeutics's estimated revenue per employee is $189,100
  • TORL Biotherapeutics's total funding is $358M.

Employee Data

  • TORL Biotherapeutics has 50 Employees.(i)
  • TORL Biotherapeutics grew their employee count by 47% last year.

TORL Biotherapeutics's People

NameTitleEmail/Phone
1
Chairman & CEOReveal Email/Phone
2
Director, President, CFO & Co-FounderReveal Email/Phone
3
Chief Medical Officer, PharmaceuticalsReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
VP, Translational ResearchReveal Email/Phone
7
SVP, Development Team LeadReveal Email/Phone
8
Associate VP, Legal Affairs & Data PrivacyReveal Email/Phone
9
VP, Head Regulatory AffairsReveal Email/Phone
10
SVP IP and Legal AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is TORL Biotherapeutics?

TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for promising, and novel cancer targets.

keywords:N/A

$358M

Total Funding

50

Number of Employees

$9.5M

Revenue (est)

47%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M5019%N/A
#2
$11.5M51-7%N/A
#3
$6.8M52-5%N/A
#4
$12.9M53-16%N/A
#5
$12.9M5310%N/A